14,745
Views
24
CrossRef citations to date
0
Altmetric
Articles

Epigenetics: from the past to the present

, &
Pages 347-370 | Received 06 Jul 2016, Accepted 10 Oct 2016, Published online: 01 Dec 2016
 

ABSTRACT

The definition of epigenetics is still under intense debate; however, its concept has evolved since it was originally introduced in 1939 by Conrad Hal Waddington as a way to reconcile antagonistic views between the school of preformationism and the school of epigenesis. The characterization of a large number of phenomena that diverge from the dogmas of classical genetics, and the discovery of the molecular mechanisms through which these phenomena occur, has given rise to a new area of study with important implications for biological sciences. Interactions between the environment and the DNA through modifications on the chromatin are not only responsible for the expression of a normal phenotype, these may be involved in the development of various pathologies. The epigenome, as the bridge between the genome and the phenotype, is no doubt one of the most interesting current ideas in genetics and is so revolutionary that it may change our present notions about inheritance and evolution. In this review, we made a compilation of the most important events in the history of epigenetics, its implications and some perspectives to the future.

Abbreviations: DNA: deoxyribonucleic acid; RNA: ribonucleic acid; DNMT: DNA methyltransferase; MBP: methyl-CpG-binding proteins; HAT: histone acetyltransferase; HDAC: histone deacetylase; SAM: S-adenosyl methionine; ncRNA: non-coding RNA; rRNA: ribosomal RNA; miRNA: microRNA; siRNA: small interfering RNA; piRNA: Piwi-interacting RNA; XiRNA: X-inactivation RNA; lncRNA: long non-coding RNA; GR: glucocorticoid receptor; IGF2: insulin-like growth factor II; HPA: hypothalamic–pituitary–adrenal; TSA: trichostatin A; LINE: long interspersed nuclear elements; LOI: loss of genomic imprinting; MAS: McCune–Albright syndrome; AS: Angelman syndrome; PWS: Prader–Willi syndrome; FDA: Food and Drug Administration; AHEAD: International Human Epigenome Project; HEP: Human Epigenome Project; TMG: thiomethyl-β-D-galactoside

Acknowledgements

The authors thank Maria Elena Torres Padilla for the critical revision of this manuscript and Jorge Eugenio Reynoso Jiménez for his help in figures preparation. NAVS acknowledges support by CONACYT and PIFI-BEIFI-IPN for the scholarships provided.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by 20131804 and 20144028 SIP-IPN grants and 84557 CONACYT grant (JMGP) and the Tertiary Education Commission New Zealand to the Bio-Protection Research Centre (AMM). JMGP is supported by COFAA and EDI-IPN fellowships. JMGP is National Researcher, Mexico.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.